Related references
Note: Only part of the references are listed.Analyzing Frequently Mutated Genes and the Association With Tumor Mutation Load
Yosef E. Maruvka et al.
JAMA ONCOLOGY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Tumor Mutation Burden-From Hopes to Doubts
Alfredo Addeo et al.
JAMA ONCOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Alicia Latham et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Qingzhu Jia et al.
JCI INSIGHT (2019)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
DNA mismatch repair in cancer
Marina Baretti et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Mutation load estimation model as a predictor of the response to cancer immunotherapy
Guan-Yi Lyu et al.
NPJ GENOMIC MEDICINE (2018)
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade
Zhijie Wang et al.
CANCER RESEARCH (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
CANCER IMMUNOTHERAPY Macrophages steal the show
M. Teresa Villanueva
NATURE REVIEWS DRUG DISCOVERY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (vol 29, pg 285, 2016)
Haidong Tang et al.
CANCER CELL (2016)
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Jaegil Kim et al.
NATURE GENETICS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Yoshinari Asaoka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Clinical Relevance of Microsatellite Instability in Colorectal Cancer
Albert de la Chapelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma
T. J. Seng et al.
BRITISH JOURNAL OF CANCER (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
